PMID-12533768 – Livagen Effects on Chromatin Activation in Old People Lymphocytes
Lezhava TA, Khavinson VKh. Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bull Exp Biol Med. 2002;134(4):389-392.
Quick Reference
| Property | Value |
|---|---|
| PMID | 12533768 |
| DOI | 10.1023/A:1021912232319 |
| Year | 2002 |
| Journal | Bulletin of Experimental Biology and Medicine |
| Study Type | In vitro |
| Evidence Level | V |
| Sample | Cultured lymphocytes from elderly human donors |
| Peptide(s) Studied | Livagen |
Key Findings
- Livagen (Lys-Glu-Ala-Ser) induced chromatin decondensation (activation) in lymphocytes from elderly donors
- The heterochromatin-to-euchromatin transition was dose-dependent
- Livagen was more potent than Vilon at inducing chromatin remodeling in this assay
- The effect supports the hypothesis that tetrapeptides interact with chromatin to regulate gene expression in aged cells
Study Design
In vitro study using peripheral blood lymphocytes from elderly human subjects. Cells were cultured with Livagen at various concentrations and chromatin condensation state was assessed using cytogenetic techniques.
Limitations
- In vitro study only
- Small donor sample
- All authors from the Khavinson group
- Chromatin remodeling does not prove functional gene expression changes
- No independent replication
Clinical Relevance
Provides the key mechanistic data for Livagen's proposed hepatoprotective action — the chromatin decondensation mechanism. However, the study was performed in lymphocytes, not hepatocytes, and clinical translation is undemonstrated.
Methodological Note: This study originates from the Khavinson bioregulation group. Independent replication by Western laboratories is lacking.
Related
#research #in-vitro #evidence-level-V #khavinson-bioregulator #peptide-livagen